Insider Selling: Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $11,673.36 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.92, for a total transaction of $11,673.36. Following the completion of the transaction, the director owned 82,027 shares in the company, valued at approximately $1,716,004.84. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 0.7%

PTHS stock opened at $22.90 on Thursday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.15 and a current ratio of 2.05. The stock has a 50 day moving average of $22.76. The company has a market capitalization of $76.94 million, a PE ratio of -1.10 and a beta of 3.93. Pelthos Therapeutics Inc. has a 1-year low of $9.00 and a 1-year high of $54.29.

Analyst Ratings Changes

A number of research analysts have commented on PTHS shares. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Piper Sandler started coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price target on the stock. Roth Mkm reduced their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Institutional Trading of Pelthos Therapeutics

Institutional investors have recently made changes to their positions in the stock. Ikarian Capital LLC boosted its stake in shares of Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after purchasing an additional 193,307 shares during the period. Boothbay Fund Management LLC boosted its stake in shares of Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after purchasing an additional 59,435 shares during the period. J. Goldman & Co LP purchased a new stake in shares of Pelthos Therapeutics during the fourth quarter valued at approximately $2,418,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Pelthos Therapeutics during the fourth quarter valued at approximately $1,085,000. Finally, Diadema Partners LP boosted its stake in shares of Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after purchasing an additional 14,502 shares during the period. Hedge funds and other institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).